Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data

• Published in: Postępy w kardiologii interwencyjnej Vol. 14; no. 2; pp. 144 - 148
• Main Authors: Briede, Ieva, Narbute, Inga, Kumsars, Indulis, Sondore, Dace, Trushinskis, Karlis, Jegere, Sanda, Latkovskis, Gustavs, Strenge, Karlis, Rudzitis, Ainars, Erglis, Andrejs
• Format: Journal Article
• Language: English
• Published: Poland Termedia Publishing House 01.01.2018
• Subjects: Acute coronary syndromes; Angina pectoris; Cardiology; Heart attacks; Original Paper; Patients; Thrombosis; scaffold thrombosis; bioresorbable vascular scaffold; percutaneous coronary intervention
• ISSN: 1734-9338; 1897-4295
• DOI: 10.5114/aic.2018.76405

The aim of this long-term registry data was to evaluate 2-year clinical and angiographic outcomes after implantation of everolimus-eluting bioresorbable scaffolds (Absorb) from the Latvian Centre of Cardiology Real-life Registry. Between November 2012 and December 2014 in the Centre of Cardiology Real-life Bioresorbable Vascular Scaffold Registry, 187 patients with stable angina or acute coronary syndrome and available 2-year follow-up were selected. All patients had percutaneous coronary intervention (PCI) following bioresorbable scaffold (Absorb) implantation. At 2 years, clinical parameters were analysed in stable angina and acute coronary syndrome subgroups: all-cause death, cardiac death, non-cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), scaffold thrombosis (ST), cerebral infarction, in-scaffold restenosis and bleeding. The clinical follow-up rate at 2 years was 96.2%. In-hospital death occurred in 2 (1.1%) patients, and 1 (0.5%) patient had in-hospital MI. At 2 years, the rate of all-cause death was 3.9% ( = 7), MI 1.6% ( = 3), TLR 3.9% ( = 7), and TVR 8.4% ( = 15). Between hospital discharge and 2-year follow-up scaffold thrombosis occurred in 2 (1.1%) patients. In-hospital scaffold thrombosis occurred in 1 (0.5%) patient due to clopidogrel resistance, and 1 additional case of scaffold thrombosis occurred at 5 days after implantation (0.5%). Bioresorbable scaffolds showed acceptable efficacy (target lesion revascularization) and safety (cardiac death, myocardial infarction, and scaffold thrombosis) results at mid-term follow-up in stable angina and acute coronary syndrome patients.